When was Suono Bio founded?

Suono Bio was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Suono Bio located?

Suono Bio is headquartered in Cambridge, United States.

How many employees does Suono Bio have?

As of Aug 31, 2026, the latest employee count at Suono Bio is 3.

Is Suono Bio a funded company?

Suono Bio is a funded company, having raised a total of $12.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 19, 2017.

When was the latest funding round of Suono Bio?

Suono Bio's latest funding was a $***** Series B round on Aug 25, 2023, with participation from 0 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $245M in funding in 2026 to date.

Where does Suono Bio rank among its competitors?

Suono Bio ranks 625th amongst 3759 active competitors, of which 962 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Suono Bio?

Suono Bio's top competitors include Jazz Pharmaceuticals, WuXi AppTec and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Suono Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract. The device they have developed can be used for the treatment of inflammatory bowel disease, cancer, and infectious GI conditions. The technology was initiated in the research laboratories at MIT.

Website: www.suonobio.com/
Social
Email ID: *****@suonobio.com

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Series B

Total Funding

$12.7M in 5 rounds

Latest Funding Round

Series B, Aug 25, 2023, $*****

Investors

Mizuho Sc & 10 more

Ranked

625^th among 3759 active competitors

Employee Count

3 as on Aug 31, 2026

Similar Companies

Barinthus Biotherapeutics & 289 more

View Suono Bio's full profile

Suono Bio has raised a total funding of $12.7M over 5 rounds. Its first funding round was on Sep 19, 2017. Suono Bio has 11 institutional investors.

Here is the list of recent funding rounds of Suono Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2023	7687759	Series B	7232810	5442751	9924614	9767564
Jul 07, 2021	9593689	Series B	9126596	4261445	1980629	Taiwania Capital
Apr 21, 2020	7644156	Series A	8317706	4943927	6662393	Niterra

Access funding benchmarks and valuations. Sign up today!

View details of Suono Bio's funding rounds and investors

The founders of Suono Bio is C Giovanni Traverso.

Here are the details of Suono Bio's key team members:

C Giovanni Traverso: Co-Founder of Suono Bio and founder of 6 other companies, including Teal Bio, Celero Systems and Syntis.

View details of Suono Bio's Founder profiles and Board Members

Suono Bio's employee count trend

Suono Bio has 3 employees as of Aug 26. Here is Suono Bio's employee count trend over the years:

Uncover Suono Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Suono Bio include Jazz Pharmaceuticals, WuXi AppTec and Sana Biotechnology. Here is the list of Top 10 competitors of Suono Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
625th	Suono Bio 2015, Cambridge (United States), Series B	Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract	$12.7M	Taiwania Capital, Fujifilm & 9 others	46/100